Real-world experience of imatinib in pediatric chronic phase-chronic myeloid leukaemia: a single center experience from India

Chronic myeloid leukaemia is a rare malignancy in children predominantly seen in adolescence with relatively aggressive disease biology compared to adults. Despite practical constraints like poor treatment adherence and financial unaffordability of second-generation tyrosine kinase inhibitors as major challenges in management, 5-year OS and EFS of 92% and 64% respectively were achieved in our study cohort with imatinib as frontline therapy. Dose augmentation of imatinib is a reasonable option in those with suboptimal response.

Source: Clinical Lymphoma, Myeloma and Leukemia - March 5, 2020 Category: Hematology Authors: Shuvadeep Ganguly, Deepam Pushpam, Agrima Mian, Anita Chopra, Ritu Gupta, Sameer Bakhshi Tags: Original Study Source Type: research